Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC and Evgen Pharma to explore treatment for osteoarthritis
Researchers will investigate the potential of the drug SFX-01 as a treatment for osteoarthritis.
Work will build on a previous collaboration

The RVC and Evgen pharma have secured funding from the Biotechnology and Biological Sciences Research Council (BBSRC) for a four-year PhD studentship focused on investigating treatment for osteoarthritis.

The Industrial Co-operative Awards in Science & Technology (CASE) PhD Studentship will allow researchers to investigate the potential of the drug SFX-01 as a treatment for the disease, which affects almost 9 million people across the UK.

The work will build on a previous collaboration, which showed that mice with spontaneously-arising osteoarthritis demonstrated significantly improved bone architecture and preservation of normal movement following three months of SFX-01 treatment.

Professor Andrew Pitsillides, who led the study, said: “Myself and my colleagues Drs Isabel Orriss and Behzad Javaheri in the RVC’s Skeletal Biology Group are very excited by the prospect of working with Evgen Pharma to identify the cellular and molecular targets by which SFX-01 exerts its beneficial actions in osteoarthritis.”

Evgen Pharma is a clinical stage drug development company that focuses on the treatment of cancer and neurological conditions.

CEO Dr Stephen Franklin commented: “As a Company, we remain focused on the delivery of our current Company sponsored clinical trials and our strategic focus is in cancer and neurology. 

“We will, however, provide SFX-01 to a limited number of world leading academics and clinical groups that wish to investigate SFX-01 in alternative therapeutic areas if they can demonstrate a robust clinical plan, source their own non-dilutive grant funding and we retain commercialisation rights.

“We, and the RVC, are delighted that the BBSRC is funding this programme and it is another step towards the possibility of a future, grant funded, clinical trial on SFX-01 in osteoarthritis”. 

Become a member or log in to add this story to your CPD history

Gucci pledges to go fur-free

News Story 1
 Italian fashion house Gucci has announced that it will no longer use animal fur in its designs. Gucci’s president & CEO Marco Bizzarri made the announcement on Wednesday (October 11) at The London College of Fashion.

The move follows a long-standing relationship with The Humane Society of the United States and LAV - members of the international Fur Free alliance. Gucci’s fur-free policy includes mink, coyote, raccoon dog, fox, rabbit, karakul and all other species bred or caught for fur.  

News Shorts
Avian flu text alert service launched in Northern Ireland

A new text system to alert bird keepers to the threat of avian flu has been launched in Northern Ireland. The service will enable bird keepers to take action to protect their flock at the earliest opportunity.

Keepers who have already provided NI's Department of Agriculture with a valid mobile number have automatically been subscribed to the service and notified by text. Bird keepers who have not yet received a text should text ‘BIRDS’ to 67300 to register.